Seres Therapeutics, Inc. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ace9f6c4-54b4-4b26-a401-3c98c2733263/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $5.7M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-103276 |
| FY 2024 | $136.0k | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038427 |
| FY 2023 | $-113.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-025464 |
| FY 2022 | $-250.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006374 |
| FY 2021 | $-65.6M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002435 |
| FY 2020 | $-89.1M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-010057 |
| FY 2019 | $-70.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-008002 |
| FY 2018 | $-98.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006423 |
| FY 2017 | $-89.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004830 |
| FY 2016 | $-91.6M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004551 |
| FY 2015 | $-54.8M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014692 |
| FY 2014 | $-16.7M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-014692 |
| FY 2013 | $-6.1M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-014692 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Seres Therapeutics, Inc. — all facts · Revenue · Operating Income